Urology · Blue Ash, OH
NPI
1275579856
Since 2006
Specialty
Urology
Code 208800000X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
10220 Alliance Rd
Blue Ash, OH, 45242
Phone (513) 841-7800
Groups this clinician bills Medicare through
Medicare paid, 2024
$711K
19,771 services
Medicare patients, 2024
1,039
Average age 75
Drug cost, 2024
$7.8M
3,387 prescriptions
Company payments, 2025
$6,260
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark G Delworth Jr. was code J0897 (injection, denosumab, 1 mg), 6,660 times for 38 patients. In total Mark G Delworth Jr. billed 19,771 services in 136 codes, and Medicare paid $711K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-12-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 6,660 | 38 | $20.20 | $135K |
| J1952 Leuprolide injectable, camcevi, 1 mg | Office | 2,436 | 39 | $45.64 | $111K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 1,801 | 19 | $0.10 | $184 |
| 99214 Office E&M - Established | Office | 1,110 | 700 | $89.37 | $99K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 980 | 659 | $11.16 | $11K |
| 36415 Venipuncture Blood Collection | Office | 926 | 498 | $8.65 | $8,010 |
| 81002 Clinical Chemistry | Office | 861 | 601 | $3.38 | $2,910 |
| 84153 Clinical Chemistry | Office | 853 | 469 | $18.00 | $15K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 629 | 138 | $49.10 | $31K |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 321 | 62 | $136.33 | $44K |
| 84403 Clinical Chemistry | Office | 309 | 113 | $25.29 | $7,815 |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 274 | 110 | $38.35 | $11K |
| 51798 Ultrasound - Nonspecific | Office | 188 | 167 | $7.27 | $1,367 |
| 96402 Chemotherapy Administration | Office | 162 | 76 | $27.20 | $4,407 |
| 80053 Clinical Chemistry | Office | 127 | 53 | $10.35 | $1,314 |
By year: 2022 $505K for 18,445 services; 2023 $648K for 20,313 services; 2024 $711K for 19,771 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 926 | 498 | $8.65 | $8,010 |
| 81002 Clinical Chemistry | 861 | 601 | $3.38 | $2,910 |
| 84153 Clinical Chemistry | 853 | 469 | $18.00 | $15K |
| 84403 Clinical Chemistry | 309 | 113 | $25.29 | $7,815 |
| 80053 Clinical Chemistry | 127 | 53 | $10.35 | $1,314 |
| 84154 Clinical Chemistry | 114 | 89 | $18.02 | $2,054 |
| 86316 Immunoassay | 112 | 88 | $20.39 | $2,284 |
| 85027 Blood Count | 63 | 50 | $6.34 | $399 |
| 87086 Bacterial Culture | 53 | 49 | $7.91 | $419 |
| 80048 Clinical Chemistry | 52 | 47 | $8.29 | $431 |
Medicare prescription drug claims, 2024
In 2024, the drug Mark G Delworth Jr. prescribed most often to Medicare patients was Tamsulosin Hcl, with 778 prescriptions and refills. In total Mark G Delworth Jr. wrote 3,387 Medicare prescriptions that cost $7.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 778 | 2,200 | 236 | $11K |
| Finasteride Generic | 378 | 1,104 | 108 | $4,448 |
| Xtandi Enzalutamide | 342 | 351 | 36 | $4.5M |
| Abiraterone Acetate Generic | 231 | 239 | 28 | $208K |
| Prednisone Generic | 218 | 248 | 33 | $1,030 |
| Orgovyx Relugolix | 157 | 157 | 21 | $419K |
| Ciprofloxacin Hcl Generic | 124 | 124 | 95 | $585 |
| Cephalexin Generic | 124 | 138 | 90 | $557 |
| Myrbetriq Mirabegron | 103 | 168 | 25 | $75K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 99 | 99 | 92 | $461 |
| Alfuzosin Hcl Er Alfuzosin Hcl | 81 | 245 | 30 | $1,732 |
| Erleada Apalutamide | 77 | 90 | Under 11 | $1.2M |
| Oxybutynin Chloride Er Oxybutynin Chloride | 69 | 204 | 25 | $2,202 |
| Nubeqa Darolutamide | 41 | 41 | Under 11 | $553K |
| Dutasteride Generic | 35 | 105 | Under 11 | $728 |
Brand drugs: 890 claims; generic drugs: 2,497 claims; opioid claims: 112.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark G Delworth Jr. $6,260 ($6,260 in general payments such as food, travel and fees) from 25 companies. The largest payer was Avyxa Pharma, LLC with $3,258.
| Company | Payments | Amount |
|---|---|---|
| Avyxa Pharma, LLC | 7 | $3,258 |
| Boston Scientific Corporation BSX | 9 | $434 |
| Dendreon Pharmaceuticals LLC | 10 | $309 |
| Janssen Biotech, Inc. JNJ | 8 | $272 |
| Calyxo, Inc. | 1 | $264 |
| Sumitomo Pharma America, Inc. 4506.T | 11 | $203 |
| Ferring Pharmaceuticals Inc. | 8 | $188 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 8 | $188 |
| Intuitive Surgical, Inc. ISRG | 2 | $180 |
| Astellas Pharma US Inc 4503.T | 8 | $135 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.